RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cytokinetics Stock

Cytokinetics P/S 2024

Cytokinetics P/S

787.96

Ticker

CYTK

ISIN

US23282W6057

WKN

A1W1KK

As of Dec 18, 2024, Cytokinetics's P/S ratio stood at 787.96, a 61.94% change from the 486.59 P/S ratio recorded in the previous year.

The Cytokinetics P/S history

Cytokinetics Aktienanalyse

What does Cytokinetics do?

Cytokinetics Inc. is a biotechnology company that was founded in 1998 and is headquartered in South San Francisco, California. The company focuses on developing novel therapies for diseases of the nervous system, cardiovascular system, and muscles. Cytokinetics develops its drugs by identifying proteins and molecules that have potential for treating diseases. The company's business model is based on the development of therapies that target the improvement of muscle strength and function. Cytokinetics is known for its innovative drug classes such as myosin inhibitors and activators, as well as its novel drug CK-274. The company offers various products aimed at improving muscle strength and function, including CK-274, a myosin inhibitor currently in phase III development for the treatment of hypertrophic cardiomyopathy. Cytokinetics is also the developer of Omecamtiv Mecarbil, a myosin activator for the treatment of heart failure, and SMN2 splicing modulators for improving SMN protein synthesis in patients with spinal muscular atrophy. The company has established partnerships with leading pharmaceutical companies for the further development and commercialization of its drugs. With its innovative therapies and industry expertise, Cytokinetics has become one of the leading biotechnology companies in the United States focused on improving muscle strength and function. Cytokinetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Cytokinetics's P/S Ratio

Cytokinetics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Cytokinetics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Cytokinetics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Cytokinetics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Cytokinetics stock

What is the price-to-earnings ratio of Cytokinetics?

The price-earnings ratio of Cytokinetics is currently 787.96.

How has the price-earnings ratio of Cytokinetics changed compared to last year?

The price-to-earnings ratio of Cytokinetics has increased by 61.94% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Cytokinetics high compared to other companies?

Yes, the price-to-earnings ratio of Cytokinetics is high compared to other companies.

How does an increase in the price-earnings ratio of Cytokinetics affect the company?

An increase in the price-earnings ratio of Cytokinetics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Cytokinetics affect the company?

A decrease in the price-earnings ratio of Cytokinetics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Cytokinetics?

Some factors that influence the price-earnings ratio of Cytokinetics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Cytokinetics pay?

Over the past 12 months, Cytokinetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cytokinetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Cytokinetics?

The current dividend yield of Cytokinetics is .

When does Cytokinetics pay dividends?

Cytokinetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cytokinetics?

Cytokinetics paid dividends every year for the past 0 years.

What is the dividend of Cytokinetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cytokinetics located?

Cytokinetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cytokinetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cytokinetics from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Cytokinetics pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Cytokinetics in the year 2023?

In the year 2023, Cytokinetics distributed 0 USD as dividends.

In which currency does Cytokinetics pay out the dividend?

The dividends of Cytokinetics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cytokinetics

Our stock analysis for Cytokinetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cytokinetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.